0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Fatty Acid Oxidation Disorders Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-18U13041
Home | Market Reports | Health| Pharmacy
Global Drugs for Fatty Acid Oxidation Disorders Market Research Report 2023
BUY CHAPTERS

Global Drugs for Fatty Acid Oxidation Disorders Market Research Report 2025

Code: QYRE-Auto-18U13041
Report
May 2025
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Drugs for Fatty Acid Oxidation Disorders Market Size

The global market for Drugs for Fatty Acid Oxidation Disorders was valued at US$ 15030 million in the year 2024 and is projected to reach a revised size of US$ 25730 million by 2031, growing at a CAGR of 8.1% during the forecast period.

Drugs for Fatty Acid Oxidation Disorders Market

Drugs for Fatty Acid Oxidation Disorders Market

Fatty Acid Oxidation Disorders (FAODs) are a group of rare genetic metabolic disorders that impair the body"s ability to break down fatty acids for energy. These disorders result from deficiencies in enzymes or transport proteins involved in the process of fatty acid oxidation. The inability to properly metabolize fatty acids can lead to energy deprivation and the accumulation of toxic byproducts, particularly during periods of fasting or increased energy demand.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Fatty Acid Oxidation Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Fatty Acid Oxidation Disorders.
The Drugs for Fatty Acid Oxidation Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Fatty Acid Oxidation Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Fatty Acid Oxidation Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Drugs for Fatty Acid Oxidation Disorders Market Report

Report Metric Details
Report Name Drugs for Fatty Acid Oxidation Disorders Market
Accounted market size in year US$ 15030 million
Forecasted market size in 2031 US$ 25730 million
CAGR 8.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Designated Pharmacy
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Biosynth AG, Daiichi Sankyo, Northeast Pharmaceutical Group, Merck KGaA, Mylan Laboratories Limited, AminoScience, Chengda Pharmaceuticals, Sigma-Tau Pharmaceuticals, Bedford Laboratories, Spectrum Chemicals, Laboratory Products
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Drugs for Fatty Acid Oxidation Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Drugs for Fatty Acid Oxidation Disorders Market growing?

Ans: The Drugs for Fatty Acid Oxidation Disorders Market witnessing a CAGR of 8.1% during the forecast period 2025-2031.

What is the Drugs for Fatty Acid Oxidation Disorders Market size in 2031?

Ans: The Drugs for Fatty Acid Oxidation Disorders Market size in 2031 will be US$ 25730 million.

Who are the main players in the Drugs for Fatty Acid Oxidation Disorders Market report?

Ans: The main players in the Drugs for Fatty Acid Oxidation Disorders Market are Biosynth AG, Daiichi Sankyo, Northeast Pharmaceutical Group, Merck KGaA, Mylan Laboratories Limited, AminoScience, Chengda Pharmaceuticals, Sigma-Tau Pharmaceuticals, Bedford Laboratories, Spectrum Chemicals, Laboratory Products

What are the Application segmentation covered in the Drugs for Fatty Acid Oxidation Disorders Market report?

Ans: The Applications covered in the Drugs for Fatty Acid Oxidation Disorders Market report are Hospital, Designated Pharmacy, Others

What are the Type segmentation covered in the Drugs for Fatty Acid Oxidation Disorders Market report?

Ans: The Types covered in the Drugs for Fatty Acid Oxidation Disorders Market report are Levocarnitine, Dextrose, Riboflavin, Others

Recommended Reports

Metabolic Disease Drugs

Rare & Genetic Disorders

Disorder & Disease Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Levocarnitine
1.2.3 Dextrose
1.2.4 Riboflavin
1.2.5 Others
1.3 Market by Application
1.3.1 Global Drugs for Fatty Acid Oxidation Disorders Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Designated Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Fatty Acid Oxidation Disorders Market Perspective (2020-2031)
2.2 Global Drugs for Fatty Acid Oxidation Disorders Growth Trends by Region
2.2.1 Global Drugs for Fatty Acid Oxidation Disorders Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drugs for Fatty Acid Oxidation Disorders Historic Market Size by Region (2020-2025)
2.2.3 Drugs for Fatty Acid Oxidation Disorders Forecasted Market Size by Region (2026-2031)
2.3 Drugs for Fatty Acid Oxidation Disorders Market Dynamics
2.3.1 Drugs for Fatty Acid Oxidation Disorders Industry Trends
2.3.2 Drugs for Fatty Acid Oxidation Disorders Market Drivers
2.3.3 Drugs for Fatty Acid Oxidation Disorders Market Challenges
2.3.4 Drugs for Fatty Acid Oxidation Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Fatty Acid Oxidation Disorders Players by Revenue
3.1.1 Global Top Drugs for Fatty Acid Oxidation Disorders Players by Revenue (2020-2025)
3.1.2 Global Drugs for Fatty Acid Oxidation Disorders Revenue Market Share by Players (2020-2025)
3.2 Global Drugs for Fatty Acid Oxidation Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drugs for Fatty Acid Oxidation Disorders Revenue
3.4 Global Drugs for Fatty Acid Oxidation Disorders Market Concentration Ratio
3.4.1 Global Drugs for Fatty Acid Oxidation Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Fatty Acid Oxidation Disorders Revenue in 2024
3.5 Global Key Players of Drugs for Fatty Acid Oxidation Disorders Head office and Area Served
3.6 Global Key Players of Drugs for Fatty Acid Oxidation Disorders, Product and Application
3.7 Global Key Players of Drugs for Fatty Acid Oxidation Disorders, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Fatty Acid Oxidation Disorders Breakdown Data by Type
4.1 Global Drugs for Fatty Acid Oxidation Disorders Historic Market Size by Type (2020-2025)
4.2 Global Drugs for Fatty Acid Oxidation Disorders Forecasted Market Size by Type (2026-2031)
5 Drugs for Fatty Acid Oxidation Disorders Breakdown Data by Application
5.1 Global Drugs for Fatty Acid Oxidation Disorders Historic Market Size by Application (2020-2025)
5.2 Global Drugs for Fatty Acid Oxidation Disorders Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drugs for Fatty Acid Oxidation Disorders Market Size (2020-2031)
6.2 North America Drugs for Fatty Acid Oxidation Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025)
6.4 North America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Fatty Acid Oxidation Disorders Market Size (2020-2031)
7.2 Europe Drugs for Fatty Acid Oxidation Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025)
7.4 Europe Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size (2020-2031)
8.2 Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size by Region (2020-2025)
8.4 Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Fatty Acid Oxidation Disorders Market Size (2020-2031)
9.2 Latin America Drugs for Fatty Acid Oxidation Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025)
9.4 Latin America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size (2020-2031)
10.2 Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025)
10.4 Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biosynth AG
11.1.1 Biosynth AG Company Details
11.1.2 Biosynth AG Business Overview
11.1.3 Biosynth AG Drugs for Fatty Acid Oxidation Disorders Introduction
11.1.4 Biosynth AG Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.1.5 Biosynth AG Recent Development
11.2 Daiichi Sankyo
11.2.1 Daiichi Sankyo Company Details
11.2.2 Daiichi Sankyo Business Overview
11.2.3 Daiichi Sankyo Drugs for Fatty Acid Oxidation Disorders Introduction
11.2.4 Daiichi Sankyo Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.2.5 Daiichi Sankyo Recent Development
11.3 Northeast Pharmaceutical Group
11.3.1 Northeast Pharmaceutical Group Company Details
11.3.2 Northeast Pharmaceutical Group Business Overview
11.3.3 Northeast Pharmaceutical Group Drugs for Fatty Acid Oxidation Disorders Introduction
11.3.4 Northeast Pharmaceutical Group Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.3.5 Northeast Pharmaceutical Group Recent Development
11.4 Merck KGaA
11.4.1 Merck KGaA Company Details
11.4.2 Merck KGaA Business Overview
11.4.3 Merck KGaA Drugs for Fatty Acid Oxidation Disorders Introduction
11.4.4 Merck KGaA Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.4.5 Merck KGaA Recent Development
11.5 Mylan Laboratories Limited
11.5.1 Mylan Laboratories Limited Company Details
11.5.2 Mylan Laboratories Limited Business Overview
11.5.3 Mylan Laboratories Limited Drugs for Fatty Acid Oxidation Disorders Introduction
11.5.4 Mylan Laboratories Limited Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.5.5 Mylan Laboratories Limited Recent Development
11.6 AminoScience
11.6.1 AminoScience Company Details
11.6.2 AminoScience Business Overview
11.6.3 AminoScience Drugs for Fatty Acid Oxidation Disorders Introduction
11.6.4 AminoScience Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.6.5 AminoScience Recent Development
11.7 Chengda Pharmaceuticals
11.7.1 Chengda Pharmaceuticals Company Details
11.7.2 Chengda Pharmaceuticals Business Overview
11.7.3 Chengda Pharmaceuticals Drugs for Fatty Acid Oxidation Disorders Introduction
11.7.4 Chengda Pharmaceuticals Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.7.5 Chengda Pharmaceuticals Recent Development
11.8 Sigma-Tau Pharmaceuticals
11.8.1 Sigma-Tau Pharmaceuticals Company Details
11.8.2 Sigma-Tau Pharmaceuticals Business Overview
11.8.3 Sigma-Tau Pharmaceuticals Drugs for Fatty Acid Oxidation Disorders Introduction
11.8.4 Sigma-Tau Pharmaceuticals Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.8.5 Sigma-Tau Pharmaceuticals Recent Development
11.9 Bedford Laboratories
11.9.1 Bedford Laboratories Company Details
11.9.2 Bedford Laboratories Business Overview
11.9.3 Bedford Laboratories Drugs for Fatty Acid Oxidation Disorders Introduction
11.9.4 Bedford Laboratories Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.9.5 Bedford Laboratories Recent Development
11.10 Spectrum Chemicals
11.10.1 Spectrum Chemicals Company Details
11.10.2 Spectrum Chemicals Business Overview
11.10.3 Spectrum Chemicals Drugs for Fatty Acid Oxidation Disorders Introduction
11.10.4 Spectrum Chemicals Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.10.5 Spectrum Chemicals Recent Development
11.11 Laboratory Products
11.11.1 Laboratory Products Company Details
11.11.2 Laboratory Products Business Overview
11.11.3 Laboratory Products Drugs for Fatty Acid Oxidation Disorders Introduction
11.11.4 Laboratory Products Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
11.11.5 Laboratory Products Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Levocarnitine
 Table 3. Key Players of Dextrose
 Table 4. Key Players of Riboflavin
 Table 5. Key Players of Others
 Table 6. Global Drugs for Fatty Acid Oxidation Disorders Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Drugs for Fatty Acid Oxidation Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Drugs for Fatty Acid Oxidation Disorders Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Region (2020-2025)
 Table 10. Global Drugs for Fatty Acid Oxidation Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Region (2026-2031)
 Table 12. Drugs for Fatty Acid Oxidation Disorders Market Trends
 Table 13. Drugs for Fatty Acid Oxidation Disorders Market Drivers
 Table 14. Drugs for Fatty Acid Oxidation Disorders Market Challenges
 Table 15. Drugs for Fatty Acid Oxidation Disorders Market Restraints
 Table 16. Global Drugs for Fatty Acid Oxidation Disorders Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Players (2020-2025)
 Table 18. Global Top Drugs for Fatty Acid Oxidation Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Fatty Acid Oxidation Disorders as of 2024)
 Table 19. Ranking of Global Top Drugs for Fatty Acid Oxidation Disorders Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Drugs for Fatty Acid Oxidation Disorders Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Drugs for Fatty Acid Oxidation Disorders, Headquarters and Area Served
 Table 22. Global Key Players of Drugs for Fatty Acid Oxidation Disorders, Product and Application
 Table 23. Global Key Players of Drugs for Fatty Acid Oxidation Disorders, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Drugs for Fatty Acid Oxidation Disorders Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Drugs for Fatty Acid Oxidation Disorders Revenue Market Share by Type (2020-2025)
 Table 27. Global Drugs for Fatty Acid Oxidation Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Drugs for Fatty Acid Oxidation Disorders Revenue Market Share by Type (2026-2031)
 Table 29. Global Drugs for Fatty Acid Oxidation Disorders Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Drugs for Fatty Acid Oxidation Disorders Revenue Market Share by Application (2020-2025)
 Table 31. Global Drugs for Fatty Acid Oxidation Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Drugs for Fatty Acid Oxidation Disorders Revenue Market Share by Application (2026-2031)
 Table 33. North America Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Biosynth AG Company Details
 Table 49. Biosynth AG Business Overview
 Table 50. Biosynth AG Drugs for Fatty Acid Oxidation Disorders Product
 Table 51. Biosynth AG Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 52. Biosynth AG Recent Development
 Table 53. Daiichi Sankyo Company Details
 Table 54. Daiichi Sankyo Business Overview
 Table 55. Daiichi Sankyo Drugs for Fatty Acid Oxidation Disorders Product
 Table 56. Daiichi Sankyo Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 57. Daiichi Sankyo Recent Development
 Table 58. Northeast Pharmaceutical Group Company Details
 Table 59. Northeast Pharmaceutical Group Business Overview
 Table 60. Northeast Pharmaceutical Group Drugs for Fatty Acid Oxidation Disorders Product
 Table 61. Northeast Pharmaceutical Group Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 62. Northeast Pharmaceutical Group Recent Development
 Table 63. Merck KGaA Company Details
 Table 64. Merck KGaA Business Overview
 Table 65. Merck KGaA Drugs for Fatty Acid Oxidation Disorders Product
 Table 66. Merck KGaA Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 67. Merck KGaA Recent Development
 Table 68. Mylan Laboratories Limited Company Details
 Table 69. Mylan Laboratories Limited Business Overview
 Table 70. Mylan Laboratories Limited Drugs for Fatty Acid Oxidation Disorders Product
 Table 71. Mylan Laboratories Limited Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 72. Mylan Laboratories Limited Recent Development
 Table 73. AminoScience Company Details
 Table 74. AminoScience Business Overview
 Table 75. AminoScience Drugs for Fatty Acid Oxidation Disorders Product
 Table 76. AminoScience Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 77. AminoScience Recent Development
 Table 78. Chengda Pharmaceuticals Company Details
 Table 79. Chengda Pharmaceuticals Business Overview
 Table 80. Chengda Pharmaceuticals Drugs for Fatty Acid Oxidation Disorders Product
 Table 81. Chengda Pharmaceuticals Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 82. Chengda Pharmaceuticals Recent Development
 Table 83. Sigma-Tau Pharmaceuticals Company Details
 Table 84. Sigma-Tau Pharmaceuticals Business Overview
 Table 85. Sigma-Tau Pharmaceuticals Drugs for Fatty Acid Oxidation Disorders Product
 Table 86. Sigma-Tau Pharmaceuticals Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 87. Sigma-Tau Pharmaceuticals Recent Development
 Table 88. Bedford Laboratories Company Details
 Table 89. Bedford Laboratories Business Overview
 Table 90. Bedford Laboratories Drugs for Fatty Acid Oxidation Disorders Product
 Table 91. Bedford Laboratories Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 92. Bedford Laboratories Recent Development
 Table 93. Spectrum Chemicals Company Details
 Table 94. Spectrum Chemicals Business Overview
 Table 95. Spectrum Chemicals Drugs for Fatty Acid Oxidation Disorders Product
 Table 96. Spectrum Chemicals Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 97. Spectrum Chemicals Recent Development
 Table 98. Laboratory Products Company Details
 Table 99. Laboratory Products Business Overview
 Table 100. Laboratory Products Drugs for Fatty Acid Oxidation Disorders Product
 Table 101. Laboratory Products Revenue in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025) & (US$ Million)
 Table 102. Laboratory Products Recent Development
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Drugs for Fatty Acid Oxidation Disorders Picture
 Figure 2. Global Drugs for Fatty Acid Oxidation Disorders Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Type: 2024 VS 2031
 Figure 4. Levocarnitine Features
 Figure 5. Dextrose Features
 Figure 6. Riboflavin Features
 Figure 7. Others Features
 Figure 8. Global Drugs for Fatty Acid Oxidation Disorders Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Designated Pharmacy Case Studies
 Figure 12. Others Case Studies
 Figure 13. Drugs for Fatty Acid Oxidation Disorders Report Years Considered
 Figure 14. Global Drugs for Fatty Acid Oxidation Disorders Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Drugs for Fatty Acid Oxidation Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Region: 2024 VS 2031
 Figure 17. Global Drugs for Fatty Acid Oxidation Disorders Market Share by Players in 2024
 Figure 18. Global Top Drugs for Fatty Acid Oxidation Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Fatty Acid Oxidation Disorders as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Drugs for Fatty Acid Oxidation Disorders Revenue in 2024
 Figure 20. North America Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Drugs for Fatty Acid Oxidation Disorders Market Share by Country (2020-2031)
 Figure 22. United States Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Drugs for Fatty Acid Oxidation Disorders Market Share by Country (2020-2031)
 Figure 26. Germany Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Drugs for Fatty Acid Oxidation Disorders Market Share by Region (2020-2031)
 Figure 34. China Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Drugs for Fatty Acid Oxidation Disorders Market Share by Country (2020-2031)
 Figure 42. Mexico Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Drugs for Fatty Acid Oxidation Disorders Market Share by Country (2020-2031)
 Figure 46. Turkey Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Drugs for Fatty Acid Oxidation Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Biosynth AG Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 50. Daiichi Sankyo Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 51. Northeast Pharmaceutical Group Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 52. Merck KGaA Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 53. Mylan Laboratories Limited Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 54. AminoScience Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 55. Chengda Pharmaceuticals Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 56. Sigma-Tau Pharmaceuticals Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 57. Bedford Laboratories Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 58. Spectrum Chemicals Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 59. Laboratory Products Revenue Growth Rate in Drugs for Fatty Acid Oxidation Disorders Business (2020-2025)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart